Oncolytic adenovirus (OA) therapy, an emerging cancer immunotherapy, is on the rise. However, intravenous delivery of OA has not yielded success in the treatment of glioblastoma (GBM) due to inefficient blood-brain barrier (BBB) penetration and poor glioma-targeting effectiveness. Therefore, oncolytic adenovirus nanoparticles (OA@Aβ-am NPs) have been successfully designed for efficient targeted delivery to GBM. The prepared platform uses OA as the core and then interacts with apolipoprotein E (A...